RESUMO
Retinal diseases are the primary reasons for severe visual defects and irreversible blindness. Retinal diseases are also inherited and acquired. Both of them are caused by mutations in genes or disruptions in specific gene expression, which can be treated by gene-editing therapy. Clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) system is a frontier of gene-editing tools with great potential for therapeutic applications in the ophthalmology field to modify abnormal genes and treat the genome or epigenome-related retinal diseases. The CRISPR system is able to edit and trim the gene include deletion, insertion, inhibition, activation, replacing, remodeling, epigenetic alteration, and modify the gene expression. CRISPR-based genome editing techniques have indicated the enormous potential to treat retinal diseases that previous treatment was not available for them. Also, recent CRISPR genome surgery experiments have shown the improvement of patient's vision who suffered from severe visual loss. In this article, we review the applications of the CRISPR-Cas9 system in human or animal models for treating retinal diseases such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR), then we survey limitations of CRISPR system for clinical therapy.
Assuntos
Sistemas CRISPR-Cas , Retinopatia Diabética/terapia , Proteínas do Olho/genética , Edição de Genes/métodos , Amaurose Congênita de Leber/terapia , Degeneração Macular/terapia , Retinose Pigmentar/terapia , Vitreorretinopatia Proliferativa/terapia , Animais , Proteína 9 Associada à CRISPR/genética , Proteína 9 Associada à CRISPR/metabolismo , Dependovirus/genética , Dependovirus/metabolismo , Retinopatia Diabética/genética , Retinopatia Diabética/metabolismo , Retinopatia Diabética/patologia , Proteínas do Olho/metabolismo , Terapia Genética/métodos , Vetores Genéticos/química , Vetores Genéticos/metabolismo , Humanos , Amaurose Congênita de Leber/genética , Amaurose Congênita de Leber/metabolismo , Amaurose Congênita de Leber/patologia , Degeneração Macular/genética , Degeneração Macular/metabolismo , Degeneração Macular/patologia , Mutação , RNA Guia de Cinetoplastídeos/genética , RNA Guia de Cinetoplastídeos/metabolismo , Retinose Pigmentar/genética , Retinose Pigmentar/metabolismo , Retinose Pigmentar/patologia , Nucleases dos Efetores Semelhantes a Ativadores de Transcrição/genética , Nucleases dos Efetores Semelhantes a Ativadores de Transcrição/metabolismo , Vitreorretinopatia Proliferativa/genética , Vitreorretinopatia Proliferativa/metabolismo , Vitreorretinopatia Proliferativa/patologia , Nucleases de Dedos de Zinco/genética , Nucleases de Dedos de Zinco/metabolismoRESUMO
Currently, controversies regarding the optimal time-point of anti-vascular endothelial growth factor (VEGF) pretreatment before pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) still exist. To clarify this, we conducted a network meta-analysis, 26 randomized controlled trials including 1806 PDR patients were included. Compared with the sham group, performing anti-VEGF injection at preoperative (Pre-Op) 6 to 14 days could significantly improve post-operative best-corrected visual acuity (BCVA) and decrease the incidence of recurrent vitreous hemorrhage (VH). Meanwhile, it could significantly reduce the duration of surgery. Performing anti-VEGF injection at Pre-Op more than 14 days, 6 to 14 days or 1 to 5 days could significantly reduce the incidence of intra-operative bleeding, while no significant benefit existed at the end of PPV (P > 0.05). No significant difference existed between all those strategies and sham group in reducing the rate of silicone oil tamponade. Based on currently available evidence, performing the anti-VEGF pretreatment at pre-operative 6 to 14 days showed best efficacy in improving post-operative BCVA, reducing the duration of surgery and incidence of recurrent VH, it also achieves satisfactory effect in reducing the incidence of intra-operative bleeding.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Bevacizumab/uso terapêutico , Retinopatia Diabética/terapia , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/terapia , Inibidores da Angiogênese/efeitos adversos , Bevacizumab/efeitos adversos , Perda Sanguínea Cirúrgica/prevenção & controle , Retinopatia Diabética/fisiopatologia , Feminino , Humanos , Masculino , Metanálise em Rede , Duração da Cirurgia , Assistência Perioperatória , Resultado do Tratamento , Acuidade VisualRESUMO
Purpose: To evaluate the role of intrasilicone oil injection of methotrexate (MTX) at the end of vitrectomy surgery for rhegmatogenous retinal detachment (RRD) associated with proliferative vitreoretinopathy (PVR).Methods: In this prospective comparative study, pars plana vitrectomy and retinal reattachment were performed for eyes with RRD with grade C PVR. In the MTX group, 250 µg MTX was injected into the silicone oil at the end of surgery. The rate of retinal redetachment associated with PVR was assessed.Results: In total, 44 eyes of 44 patients (22 in the MTX group and 22 controls) were included. Baseline characteristics were similar between the two groups. Retinal redetachment occurred in one eye (4.5%) in the MTX group and five eyes (22.7%) in the control group (p = 0.18). The change in visual acuity was similar between the two groups at final visit (p = 0.15).Conclusion: The rate of redetachment associated with PVR was lower after intrasilicone injection of MTX at the end of vitrectomy for RRD with severe PVR compared to control group; however, the difference was not statistically significant.
Assuntos
Tamponamento Interno/métodos , Metotrexato/administração & dosagem , Descolamento Retiniano/cirurgia , Óleos de Silicone , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/complicações , Feminino , Seguimentos , Humanos , Imunossupressores/administração & dosagem , Injeções Intraoculares , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Descolamento Retiniano/etiologia , Acuidade Visual , Vitreorretinopatia Proliferativa/diagnóstico , Vitreorretinopatia Proliferativa/terapiaRESUMO
Epithelial to mesenchymal transition (EMT) plays an important role in the pathogenesis of proliferative vitreoretinopathy (PVR). We aimed to demonstrate the role of mouse double minute 2 (MDM2) in transforming growth factor-beta 2 (TGF-ß2)-induced EMT in human retinal pigment epithelial cells (RPEs). Immunofluorescence was used to assess MDM2 expression in epiretinal membranes (ERMs) from patients with PVR. A single guide (sg)RNA targeting the second promoter of MDM2 was cloned into a mutant lentiviral Clustered Regularly Interspaced Short Palindromic Repeats (lentiCRISPR) v2 (D10A and H840A) vector for expressing nuclease dead Cas9 (dCas9)/MDM2-sgRNA in RPEs. In addition, MDM2-sgRNA was also cloned into a pLV-sgRNA-dCas9-Kruppel associated box (KRAB) vector for expressing dCas9 fused with a transcriptional repressor KRAB/MDM2-sgRNA. TGF-ß2-induced expression of MDM2 and EMT biomarkers were assessed by quantitative polymerase chain reaction (q-PCR), western blot, or immunofluorescence. Wound-healing and proliferation assays were used to evaluate the role of MDM2 in TGF-ß2-induced responses in RPEs. As a result, we found that MDM2 was expressed obviously in ERMs, and that TGF-ß2-induced expression of MDM2 and EMT biomarkers Fibronectin, N-cadherin and Vimentin in RPEs. Importantly, we discovered that the dCas9/MDM2-sgRNA blocked TGF-ß2-induced expression of MDM2 and the EMT biomarkers without affecting their basal expression, whereas the dCas9-KRAB/MDM2-sgRNA suppressed basal MDM2 expression in RPEs. These cells could not be maintained continuously because their viability was greatly reduced. Next, we found that Nutlin-3, a small molecule blocking the interaction of MDM2 with p53, inhibited TGF-ß2-induced expression of Fibronectin and N-cadherin but not Vimentin in RPEs, indicating that MDM2 functions in both p53-dependent and -independent pathways. Finally, our experimental data demonstrated that dCas9/MDM2-sgRNA suppressed TGF-ß2-dependent cell proliferation and migration without disturbing the unstimulated basal activity. In conclusion, the CRISPR/dCas9 capability for blocking TGF-ß2-induced expression of MDM2 and EMT biomarkers can be exploited for a therapeutic approach to PVR.
Assuntos
Transição Epitelial-Mesenquimal , Proteínas Proto-Oncogênicas c-mdm2/metabolismo , Vitreorretinopatia Proliferativa/etiologia , Proteína 9 Associada à CRISPR , Sistemas CRISPR-Cas , Membrana Epirretiniana/metabolismo , Células HEK293 , Humanos , Proteínas Proto-Oncogênicas c-mdm2/antagonistas & inibidores , Epitélio Pigmentado da Retina/citologia , Fator de Crescimento Transformador beta2 , Vitreorretinopatia Proliferativa/metabolismo , Vitreorretinopatia Proliferativa/terapiaRESUMO
PURPOSE: To evaluate the effects of repeated intra-silicone oil (SO) injections of methotrexate (MTX) on the outcomes of surgery for rhegmatogenous retinal detachment (RRD) with grade C proliferative vitreoretinopathy (PVR-C). METHODS: In this prospective pilot case series, eyes with RRD and PVR-C underwent pars plana vitrectomy and intraocular injection of SO. At the conclusion of the procedure, 250 µg of MTX was injected into the SO-filled vitreous cavity. Intra-SO injection was repeated at weeks 3 and 6; the minimum follow-up period was 6 months. The main outcome measure was retinal reattachment rate. RESULTS: Eleven eyes of 11 patients (mean age, 52.73 ± 18.01 years) were included. The mean follow-up period was 9 ± 3 months (range, 6-15 months). Total retinal detachment with anterior and/or posterior PVR-C was present in all eyes before surgery. Mean preoperative best-corrected visual acuity (BCVA) was 2.62 ± 0.04 logMAR. All operated eyes exhibited retinal reattachment posterior to the equator during the follow-up period. Mean postoperative BCVA was significantly improved to 1.02 ± 0.51 logMAR (p = 0.003). No ocular or systemic side effects were observed. CONCLUSION: Repeated intra-SO injection of MTX as an adjunctive therapy for RRD complicated by PVR showed promising results and was not associated with adverse effects. Further studies are needed to confirm its possible beneficial effects on the final anatomic and functional outcomes in these cases.
Assuntos
Metotrexato/administração & dosagem , Descolamento Retiniano/terapia , Óleos de Silicone , Acuidade Visual , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Tamponamento Interno , Feminino , Humanos , Imunossupressores/administração & dosagem , Injeções Intraoculares , Fotocoagulação a Laser , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Estudos Prospectivos , Retina/patologia , Descolamento Retiniano/diagnóstico , Descolamento Retiniano/etiologia , Tomografia de Coerência Óptica , Resultado do Tratamento , Vitreorretinopatia Proliferativa/complicações , Vitreorretinopatia Proliferativa/diagnóstico , Adulto JovemRESUMO
Fibrosis in ocular tissues causes severe visual deterioration and blindness in patients with glaucoma, cataract, age related macular degeneration (AMD) and diabetic retinopathy (DR). Currently available anti-fibrotic agents exhibit undesirous cytotoxic effects and thus prove ineffective to treat post-surgical fibrosis. Accordingly, there is a need to develop efficient and novel anti-fibrotic agents. Adiponectin (APN), an adipokine from adipocytes is increased in the aqueous and vitreous humor of the patients with micro-angiopathy and chronic inflammation. Furthermore, it is reported to be elevated in the subretinal fluid, vitreous and epiretinal membrane of patients with AMD, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR) respectively. Since APN has anti-angiogenic activity and reduces VEGF levels, we hypothesize that APN might regulate the angio-fibrotic switch and drive the formation of fibrovascular membrane at advanced stages of AMD, PVR and PDR. Intriguingly, APN is shown to inhibit liver, cardiac and pulmonary fibrosis, yet it accelerates renal fibrosis. Therefore, the factors such as tissue and cell type, disease specific pathological milieu and the choice of APN receptor interaction could determine the pro- or anti-fibrotic nature of APN. We speculate that APN could play a profibrotic role in the posterior segment of the eye.
Assuntos
Adipócitos/metabolismo , Adiponectina/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Vitreorretinopatia Proliferativa/metabolismo , Corpo Vítreo/metabolismo , Biomarcadores/metabolismo , Retinopatia Diabética/metabolismo , Retinopatia Diabética/terapia , Fibrose/terapia , Humanos , Inflamação , Modelos Teóricos , Vitreorretinopatia Proliferativa/terapia , CicatrizaçãoAssuntos
Vitreorretinopatia Proliferativa , Inibidores da Angiogênese/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Antineoplásicos/uso terapêutico , Glucocorticoides/uso terapêutico , Humanos , Fatores de Risco , Fumar/efeitos adversos , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/fisiopatologia , Vitreorretinopatia Proliferativa/terapiaAssuntos
Diabetes Mellitus Tipo 1/diagnóstico , Retinopatia Diabética/diagnóstico , Complicações na Gravidez/diagnóstico , Gravidez em Diabéticas/diagnóstico , Vitreorretinopatia Proliferativa/diagnóstico , Adulto , Anticorpos Monoclonais/administração & dosagem , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/terapia , Retinopatia Diabética/patologia , Retinopatia Diabética/terapia , Feminino , Angiofluoresceinografia , Humanos , Achados Incidentais , Injeções Intravítreas , Fotocoagulação , Edema Macular/complicações , Edema Macular/diagnóstico , Edema Macular/terapia , Gravidez , Complicações na Gravidez/terapia , Gravidez em Diabéticas/patologia , Gravidez em Diabéticas/terapia , Tomografia de Coerência Óptica , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/imunologia , Vitreorretinopatia Proliferativa/patologia , Vitreorretinopatia Proliferativa/terapiaRESUMO
Proliferative vitreoretinal diseases such as diabetic retinopathy, proliferative vitreoretinopathy (PVR), and age-related macular degeneration are a leading cause of decreased vision and blindness in developed countries. In these diseases, retinal fibro(vascular) membrane (FVM) formation above and beneath the retina plays an important role. Gene expression profiling of human FVMs revealed significant upregulation of periostin. Subsequent analyses demonstrated increased periostin expression in the vitreous of patients with both proliferative diabetic retinopathy and PVR. Immunohistochemical analysis showed co-localization of periostin with α-SMA and M2 macrophage markers in FVMs. In vitro, periostin blockade inhibited migration and adhesion induced by PVR vitreous and transforming growth factor-ß2 (TGF-ß2). In vivo, a novel single-stranded RNAi agent targeting periostin showed the inhibitory effect on experimental retinal and choroidal FVM formation without affecting the viability of retinal cells. These results indicated that periostin is a pivotal molecule for FVM formation and a promising therapeutic target for these proliferative vitreoretinal diseases.
Assuntos
Moléculas de Adesão Celular/genética , Neovascularização de Coroide/genética , Retinopatia Diabética/genética , Degeneração Macular/genética , Vitreorretinopatia Proliferativa/genética , Actinas/genética , Actinas/imunologia , Animais , Moléculas de Adesão Celular/antagonistas & inibidores , Moléculas de Adesão Celular/imunologia , Neovascularização de Coroide/imunologia , Neovascularização de Coroide/patologia , Neovascularização de Coroide/terapia , Retinopatia Diabética/imunologia , Retinopatia Diabética/patologia , Retinopatia Diabética/terapia , Regulação da Expressão Gênica , Inativação Gênica , Humanos , Degeneração Macular/imunologia , Degeneração Macular/patologia , Degeneração Macular/terapia , Camundongos , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Retina/imunologia , Retina/patologia , Transdução de Sinais , Fator de Crescimento Transformador beta2/genética , Fator de Crescimento Transformador beta2/imunologia , Vitreorretinopatia Proliferativa/imunologia , Vitreorretinopatia Proliferativa/patologia , Vitreorretinopatia Proliferativa/terapia , Corpo Vítreo/imunologia , Corpo Vítreo/patologiaRESUMO
Endothelial colony-forming cells (ECFCs) are a defined subtype of endothelial progenitors that modulate vascular repair and promote perfusion in ischaemic tissues. Their paracrine activity on resident vasculature is ill-defined, but mediated, at least in part, by the transfer of extracellular vesicles (EVs). To evaluate the potential of isolated EVs to provide an alternative to cell-based therapies, we first performed a physical and molecular characterization of those released by ECFCs. Their effects upon endothelial cells in vitro and angiogenesis in vivo in a model of proliferative retinopathy were assessed. The EVs expressed typical markers CD9 and CD63 and formed a heterogeneous population ranging in size from ~60 to 1500 nm by electron microscopy. ECFC EVs were taken up by endothelial cells and increased cell migration. This was reflected by microarray analyses which showed significant changes in expression of genes associated with angiogenesis. Sequencing of small RNAs in ECFCs and their EVs showed that multiple microRNAs are highly expressed and concentrated in EVs. The functional categories significantly enriched for the predicted target genes of these microRNAs included angiogenesis. Intravitreally delivered ECFC EVs were associated with the vasculature and significantly reduced the avascular area in a mouse oxygen-induced retinopathy model. Our findings confirm the potential of isolated EVs to influence endothelial cell function and act as a therapy to modulate angiogenesis. The functions associated with the specific microRNAs detected in ECFC EVs support a role for microRNA transfer in mediating the observed effects.
Assuntos
Proteínas Angiogênicas/genética , Células Progenitoras Endoteliais/metabolismo , Vesículas Extracelulares/transplante , MicroRNAs/genética , Neovascularização Fisiológica/genética , Vitreorretinopatia Proliferativa/terapia , Proteínas Angiogênicas/metabolismo , Animais , Biomarcadores/metabolismo , Movimento Celular , Ensaio de Unidades Formadoras de Colônias , Modelos Animais de Doenças , Células Progenitoras Endoteliais/citologia , Vesículas Extracelulares/metabolismo , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Camundongos , Camundongos Endogâmicos C57BL , MicroRNAs/metabolismo , Análise em Microsséries , Mapeamento de Interação de Proteínas , Tetraspanina 29/genética , Tetraspanina 29/metabolismo , Tetraspanina 30/genética , Tetraspanina 30/metabolismo , Vitreorretinopatia Proliferativa/genética , Vitreorretinopatia Proliferativa/metabolismo , Vitreorretinopatia Proliferativa/patologiaRESUMO
Background Proliferative vitreoretinopathy (PVR) occurs in 10â% of patients with retinal detachment and is characterized by excessive epi-, sub- or intraretinal contraction. Corticosteroids have been shown to counter this contraction. Patients and Methods Retrospective review of 5 patients (3 females, 2 males) with recurrent retinal detachment with stage C PVR. The mean age was 61.2 ± 20.5 years and myopia > - 5.0 dioptres was present in 3 eyes. Patients were treated with 23 g vitrectomy, retinectomy and endolaser, dexamethasone (Ozurdex®) injection under perfluorocarbone and 5500 cs silicone oil tamponade. Results After a total follow-up of 8.8 ± 6.4 months with silicone oil tamponade, the Ozurdex® implant was localised in the macula in 1 case, and in 4 cases behind the iris with a completely attached retina. Preoperative intraocular pressure was 11.0 ± 4.0 mmHg, which remained stable at 7.8 ± 3.5 mmHg at the end of the final follow-up. No localised adverse effects were observed of the implant on the retina or the iris. Conclusions The dexamethasone implant Ozurdex® is well tolerated in conjunction with silicone oil tamponade in eyes with retinal detachment and PVR. The implant may be a potential candidate for the prevention of PVR.
Assuntos
Dexametasona/administração & dosagem , Implantes de Medicamento/administração & dosagem , Tamponamento Interno/métodos , Óleos de Silicone/administração & dosagem , Vitreorretinopatia Proliferativa/diagnóstico por imagem , Vitreorretinopatia Proliferativa/terapia , Adulto , Idoso , Quimioterapia Adjuvante/métodos , Feminino , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Vitreorretinopatia Proliferativa/patologiaRESUMO
Ocular hypotension is a result of a lack of production or a loss of intraocular fluid. Intraocular inflammation, drugs, or proliferative vitreoretinopathy (PVR) with overgrowth of the ciliary body can result in reduced secretion of intraocular fluid. Loss of intraocular fluid can result from external loss, such as in fistulating surgery or trauma, or internally, e.g. from cyclodialysis clefts or retinal detachment. In this review, we discuss the causal therapy of ocular hypotension: fixation of the ciliary body, removal of ciliary body membranes, surgery for PVR, choice of tamponade, possibilities and limitations of an iris diaphragm, and pharmacological options.
Assuntos
Hipotensão Ocular/diagnóstico , Hipotensão Ocular/terapia , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/terapia , Corpo Ciliar/cirurgia , Terapia Combinada/métodos , Diagnóstico Diferencial , Humanos , Hipotensão Ocular/etiologia , Resultado do Tratamento , Vitreorretinopatia Proliferativa/complicações , Vitreorretinopatia Proliferativa/diagnósticoRESUMO
BACKGROUND: Open globe ocular trauma complicated by intraocular scarring (proliferative vitreoretinopathy) is a relatively rare, blinding, but potentially treatable condition for which, at present, surgery is often unsatisfactory and visual results frequently poor. To date, no pharmacological adjuncts to surgery have been proven to be effective. The aim of the Adjunctive Steroid Combination in Ocular Trauma (ASCOT) randomised controlled trial is to determine whether adjunctive steroid (triamcinolone acetonide), given at the time of surgery, can improve the outcome of vitreoretinal surgery in patients with open globe ocular trauma. This article presents the statistical analysis plan for the main publication as approved and signed off by the Trial Steering Committee prior to the first data extraction for the Data Monitoring Committee meeting report. METHODS/DESIGN: ASCOT is a pragmatic, multi-centre, parallel-group, double-masked randomised controlled trial. The aim of the study is to recruit from 20-25 centres in the United Kingdom and randomise 300 eyes (from 300 patients) into two treatment arms. Both groups will receive standard surgical treatment and care; the intervention arm will additionally receive a pre-operative steroid combination (triamcinolone acetonide) into the vitreous cavity consisting of 4 mg/0.1 ml and 40 mg/1 ml sub-Tenon's. Participants will be followed for 6 months post-surgery. The primary outcome is the proportion of patients achieving a clinically meaning improvement in visual acuity in the study eye at 6 months after initial surgery, defined as a 10 letter score improvement in the ETDRS (the standard scale to test visual acuity). TRIAL REGISTRATION: ISRCTN30012492 . Registered on 5 September 2014. EudraCT2014-002193-37 . Registered on 5 September 2014.
Assuntos
Traumatismos Oculares/terapia , Glucocorticoides/administração & dosagem , Modelos Estatísticos , Triancinolona Acetonida/administração & dosagem , Vitrectomia , Cirurgia Vitreorretiniana , Vitreorretinopatia Proliferativa/terapia , Administração Oftálmica , Quimioterapia Adjuvante , Protocolos Clínicos , Interpretação Estatística de Dados , Método Duplo-Cego , Traumatismos Oculares/diagnóstico , Traumatismos Oculares/fisiopatologia , Glucocorticoides/efeitos adversos , Humanos , Recuperação de Função Fisiológica , Projetos de Pesquisa , Fatores de Tempo , Resultado do Tratamento , Triancinolona Acetonida/efeitos adversos , Reino Unido , Acuidade Visual/efeitos dos fármacos , Vitrectomia/efeitos adversos , Cirurgia Vitreorretiniana/efeitos adversos , Vitreorretinopatia Proliferativa/diagnóstico , Vitreorretinopatia Proliferativa/fisiopatologiaRESUMO
For decades there was a general consensus about diagnostic investigations and surgical treatment of symptomatic pathological changes in the vitreomacular interface (VMI). The introduction of SD-OCT imaging helped in the understanding of the pathogenetic processes at this interface and risk factors were defined for the macular traction syndrome, epiretinal membrane (ERM) and macular hole. After approval of ocriplasmin for non-surgical treatment, a new classification based on treatment outcome and new imaging techniques was established. Precise separation of physiological, age-related changes in the VMI and pathological changes was then possible. Clinically relevant aspects in the diagnostic testing and treatment of diseases of the VMI are reported in this literature review.
Assuntos
Oftalmoscopia/métodos , Avaliação de Resultados em Cuidados de Saúde/métodos , Tomografia de Coerência Óptica/métodos , Vitreorretinopatia Proliferativa/diagnóstico , Vitreorretinopatia Proliferativa/terapia , Diagnóstico Diferencial , Medicina Baseada em Evidências , Humanos , Seleção de Pacientes , Índice de Gravidade de Doença , Cirurgia Vitreorretiniana/efeitos adversos , Vitreorretinopatia Proliferativa/patologiaRESUMO
During the last four decades, proliferative vitreoretinopathy (PVR) has defied the efforts of many researchers to prevent its occurrence or development. Thus, PVR is still the major complication following retinal detachment (RD) surgery and a bottle-neck for advances in cell therapy that require intraocular surgery. In this review we tried to combine basic and clinical knowledge, as an example of translational research, providing new and practical information for clinicians. PVR was defined as the proliferation of cells after RD. This idea was used for classifying PVR and also for designing experimental models used for testing many drugs, none of which were successful in humans. We summarize current information regarding the pathogenic events that follow any RD because this information may be the key for understanding and treating the earliest stages of PVR. A major focus is made on the intraretinal changes derived mainly from retinal glial cell reactivity. These responses can lead to intraretinal PVR, an entity that has not been clearly recognized. Inflammation is one of the major components of PVR, and we describe new genetic biomarkers that have the potential to predict its development. New treatment approaches are analyzed, especially those directed towards neuroprotection, which can also be useful for preventing visual loss after any RD. We also summarize the results of different surgical techniques and clinical information that is oriented toward the identification of high risk patients. Finally, we provide some recommendations for future classification of PVR and for designing comparable protocols for testing new drugs or techniques.
Assuntos
Descolamento Retiniano/complicações , Vitreorretinopatia Proliferativa/etiologia , Animais , Proteínas de Transporte/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Humanos , Retina/patologia , Descolamento Retiniano/cirurgia , Fatores de Risco , Vitreorretinopatia Proliferativa/classificação , Vitreorretinopatia Proliferativa/terapia , Corpo Vítreo/patologiaAssuntos
Vitreorretinopatia Proliferativa/diagnóstico , Adulto , Inibidores da Angiogênese/uso terapêutico , Diagnóstico Diferencial , Humanos , Masculino , Miopia Degenerativa/diagnóstico , Descolamento Retiniano/diagnóstico , Esteroides/uso terapêutico , Vitrectomia/métodos , Vitreorretinopatia Proliferativa/terapiaAssuntos
Traumatismos Oculares/etiologia , Radioterapia Conformacional/efeitos adversos , Vitreorretinopatia Proliferativa/diagnóstico , Vitreorretinopatia Proliferativa/etiologia , Hemorragia Vítrea/diagnóstico , Hemorragia Vítrea/etiologia , Adulto , Diagnóstico Diferencial , Traumatismos Oculares/diagnóstico , Traumatismos Oculares/terapia , Humanos , Masculino , Resultado do Tratamento , Vitreorretinopatia Proliferativa/terapia , Hemorragia Vítrea/terapiaRESUMO
Steroids are commonly used as adjunct therapy in the management of proliferative vitreoretinopathy. The authors report a case of proliferative vitreoretinopathy treated with an intravitreal dexamethasone implant following vitrectomy in a silicone oil-filled eye. Epiretinal fibrosis developed around the implant at 6 weeks postoperatively, resulting in a recurrent retinal detachment. This was repaired by vitrectomy, removal of the implant, and peeling of epiretinal proliferation.
Assuntos
Dexametasona/administração & dosagem , Glucocorticoides/administração & dosagem , Retina/patologia , Descolamento Retiniano/cirurgia , Óleos de Silicone/administração & dosagem , Vitrectomia , Vitreorretinopatia Proliferativa/terapia , Terapia Combinada , Implantes de Medicamento , Tamponamento Interno , Fibrose , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Tomografia de Coerência ÓpticaRESUMO
Because proliferative vitreoretinopathy cannot be effectively treated, its prevention is indispensable for the success of surgery for retinal detachment. The elaboration of preventive and therapeutic strategies depends upon the identification of patients who are genetically predisposed to develop the disease, as well as upon an understanding of the biological process involved and the role of local factors, such as the status of the uveovascular barrier. Detachment of the retina or vitreous activates glia to release cytokines and ATP, which not only protect the neuroretina but also promote inflammation, retinal ischemia, cell proliferation, and tissue remodeling. The vitreal microenvironment favors cellular de-differentiation and proliferation of cells with nonspecific nutritional requirements. This may render a pharmacological inhibition of their growth difficult without causing damage to the pharmacologically vulnerable neuroretina. Moreover, reattachment of the retina relies upon the local induction of a controlled wound-healing response involving macrophages and proliferating glia. Hence, the functional outcome of proliferative vitreoretinopathy will be determined by the equilibrium established between protective and destructive repair mechanisms, which will be influenced by the location and the degree of damage to the photoreceptor cells that is induced by peri-retinal gliosis.
Assuntos
Descolamento Retiniano/fisiopatologia , Vitreorretinopatia Proliferativa/fisiopatologia , Humanos , Descolamento Retiniano/diagnóstico , Descolamento Retiniano/terapia , Fatores de Risco , Vitreorretinopatia Proliferativa/diagnóstico , Vitreorretinopatia Proliferativa/terapiaRESUMO
PURPOSE: To evaluate the effect of adjunctive subtenon injection of triamcinolone acetonide (TA) in gas-filled eyes after vitrectomy for complicated proliferative diabetic retinopathy (PDR). METHODS: This nonrandomized comparative study included 27 patients (27 eyes) who underwent pars plana vitrectomy and gas tamponade for treatment of PDR with tractional or combined tractional-rhegmatogenous retinal detachment and who received subtenon injection of TA (40 mg) at the end of surgery. The study group was compared with the control group (29 eyes), which was matched with the study group for preoperative and intraoperative parameters, but underwent pars plana vitrectomy and gas tamponade without a subtenon injection of TA. RESULTS: Retinal reattachments without reoperation were achieved in 25 eyes (92.6%) and 26 eyes (89.7%) at 6 months (p = 1.000) in the study and control groups, respectively. The study group and the control group did not differ significantly in the frequency of postoperative proliferative vitreoretinopathy, retinal redetachment rate, reoperation rate, macular pucker formation, postoperative vitreous hemorrhage, gain in visual acuity, intraocular pressure, and intraocular inflammation (p > 0.05). CONCLUSIONS: The clinical results of pars plana vitrectomy for complicated PDR are not improved significantly by an adjunctive subtenon TA injection in gas-filled eyes.